Diagnosing diabetes mellitus in patients with porphyria cutanea tarda

Anne L. Christiansen*, Anette Bygum, Ole Hother-Nielsen, Lars M. Rasmussen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

The prevalence of diabetes mellitus is increased in patients with porphyria cutanea tarda. Different tests are available for diagnosing and screening for type II diabetes mellitus, however choosing the most suitable test is challenging. The pitfalls in the different tests along with the interfering comorbidities and treatments concerning patients with porphyria cutanea tarda complicate diagnosing these patients with diabetes mellitus. HbA1c, fasting glucose, or oral glucose tolerance are the current available tests, with HbA1c as first choice. Measuring HbA1c requires no fasting, however HbA1c can be false low if the patient is treated with phlebotomy or has liver cirrhosis or chronic hepatitis. Instead fasting glucose and oral glucose tolerance tests can be used if the patient is not acutely ill. If either of the tests give a result in the diagnostic range, the test should be repeated if the patient has no clinical symptoms of diabetes. Diagnosing diabetes mellitus is important for the purpose of early intervention, and this review provides the knowledge needed to diagnose this special patient group properly.

OriginalsprogEngelsk
TidsskriftInternational Journal of Dermatology
Vol/bind57
Udgave nummer7
Sider (fra-til)763-769
ISSN0011-9059
DOI
StatusUdgivet - 1. jul. 2018

Fingeraftryk

Porphyria Cutanea Tarda
Diabetes Mellitus
Fasting
Glucose Tolerance Test
Chronic Hepatitis
Routine Diagnostic Tests
Liver Cirrhosis
Type 2 Diabetes Mellitus
Comorbidity

Citer dette

@article{82ffdc78fe1c4e188becb6f8ff71ccfd,
title = "Diagnosing diabetes mellitus in patients with porphyria cutanea tarda",
abstract = "The prevalence of diabetes mellitus is increased in patients with porphyria cutanea tarda. Different tests are available for diagnosing and screening for type II diabetes mellitus, however choosing the most suitable test is challenging. The pitfalls in the different tests along with the interfering comorbidities and treatments concerning patients with porphyria cutanea tarda complicate diagnosing these patients with diabetes mellitus. HbA1c, fasting glucose, or oral glucose tolerance are the current available tests, with HbA1c as first choice. Measuring HbA1c requires no fasting, however HbA1c can be false low if the patient is treated with phlebotomy or has liver cirrhosis or chronic hepatitis. Instead fasting glucose and oral glucose tolerance tests can be used if the patient is not acutely ill. If either of the tests give a result in the diagnostic range, the test should be repeated if the patient has no clinical symptoms of diabetes. Diagnosing diabetes mellitus is important for the purpose of early intervention, and this review provides the knowledge needed to diagnose this special patient group properly.",
author = "Christiansen, {Anne L.} and Anette Bygum and Ole Hother-Nielsen and Rasmussen, {Lars M.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/ijd.13938",
language = "English",
volume = "57",
pages = "763--769",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "7",

}

Diagnosing diabetes mellitus in patients with porphyria cutanea tarda. / Christiansen, Anne L.; Bygum, Anette; Hother-Nielsen, Ole; Rasmussen, Lars M.

I: International Journal of Dermatology, Bind 57, Nr. 7, 01.07.2018, s. 763-769.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - Diagnosing diabetes mellitus in patients with porphyria cutanea tarda

AU - Christiansen, Anne L.

AU - Bygum, Anette

AU - Hother-Nielsen, Ole

AU - Rasmussen, Lars M.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The prevalence of diabetes mellitus is increased in patients with porphyria cutanea tarda. Different tests are available for diagnosing and screening for type II diabetes mellitus, however choosing the most suitable test is challenging. The pitfalls in the different tests along with the interfering comorbidities and treatments concerning patients with porphyria cutanea tarda complicate diagnosing these patients with diabetes mellitus. HbA1c, fasting glucose, or oral glucose tolerance are the current available tests, with HbA1c as first choice. Measuring HbA1c requires no fasting, however HbA1c can be false low if the patient is treated with phlebotomy or has liver cirrhosis or chronic hepatitis. Instead fasting glucose and oral glucose tolerance tests can be used if the patient is not acutely ill. If either of the tests give a result in the diagnostic range, the test should be repeated if the patient has no clinical symptoms of diabetes. Diagnosing diabetes mellitus is important for the purpose of early intervention, and this review provides the knowledge needed to diagnose this special patient group properly.

AB - The prevalence of diabetes mellitus is increased in patients with porphyria cutanea tarda. Different tests are available for diagnosing and screening for type II diabetes mellitus, however choosing the most suitable test is challenging. The pitfalls in the different tests along with the interfering comorbidities and treatments concerning patients with porphyria cutanea tarda complicate diagnosing these patients with diabetes mellitus. HbA1c, fasting glucose, or oral glucose tolerance are the current available tests, with HbA1c as first choice. Measuring HbA1c requires no fasting, however HbA1c can be false low if the patient is treated with phlebotomy or has liver cirrhosis or chronic hepatitis. Instead fasting glucose and oral glucose tolerance tests can be used if the patient is not acutely ill. If either of the tests give a result in the diagnostic range, the test should be repeated if the patient has no clinical symptoms of diabetes. Diagnosing diabetes mellitus is important for the purpose of early intervention, and this review provides the knowledge needed to diagnose this special patient group properly.

U2 - 10.1111/ijd.13938

DO - 10.1111/ijd.13938

M3 - Review

VL - 57

SP - 763

EP - 769

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 7

ER -